<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03866603</url>
  </required_header>
  <id_info>
    <org_study_id>ROPAD 01-2019</org_study_id>
    <nct_id>NCT03866603</nct_id>
  </id_info>
  <brief_title>Rostock International Parkinson's Disease Study (ROPAD)</brief_title>
  <acronym>ROPAD</acronym>
  <official_title>Rostock International Parkinson's Disease Study: an International, Multicenter, Epidemiological Observational Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centogene AG Rostock</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centogene AG Rostock</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Rostock International Parkinson's Disease Study - An International, multicentre,
      epidemiological observational study aiming at identification of 1,500 LRRK2-positive
      patients, the identification of 1,500 non-LRRK2 PD patients and the establishment of a
      candidate biomarker in the LRRK2-positive cohort.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Parkinson's disease (PD) is one of the most common neurodegenerative disorders worldwide,
      affecting approximately 1% of individuals older than 60 years and causes progressive
      disability.

      Clinical signs and symptoms of PD include the following: asymmetric tremor at rest,
      bradykinesia, muscle rigidity, postural instability, gait abnormalities including festination
      and freezing. Onset is typically after the age of 50 years and the disease is commonly slowly
      progressive. The most common initial finding of PD is a resting tremor in the upper
      extremity. Over time, participants experience progressive bradykinesia, rigidity, and gait
      difficulty, while the axial posture becomes progressively flexed. Non-motor symptoms are
      common in all stages of Parkinson disease and they include constipation, seborrhea, hyposmia
      or anosmia, sympathetic denervation of the heart, depression and/or apathy, sleep
      disturbances, cognitive decline and dementia. They may appear prior to the movement disorder
      and can be used as preclinical markers of PD.

      PD is mostly considered as idiopathic disease; however more and more data suggest that it is
      a disease that involves interaction of genetic and environmental factors. The most common
      monogenic form and the one most closely resembling idiopathic PD is LRRK2 (Leucine-rich
      repeat kinase 2 gene) associated PD.

      The most common monogenic form and the one most closely resembling idiopathic PD is LRRK2
      (Leucine-rich repeat kinase 2 gene) associated PD. First identified in 2004, LRRK2 mutations
      are currently still the most commonly known cause of PD and account for up to ~40% of all
      Parkinson's disease cases in select populations. The majority of reported LRRK2-positive PD
      patients are Caucasian (63%), whereas all other ethnicities comprise ~10% or fewer patients
      of described mutation carriers despite clusters in the Ashkenazi Jewish and Arab Berber
      populations. With respect to country of origin, the majority of patients were re-ported to
      reside in Italy or Spain (14% each), Great Britain (10%) or Norway (9%). Definitely
      pathogenic variants identified in LRRK2 include p.G2019S, p.R1441C/G/H, p.N1437H, p.Y1699C,
      and, p.I2020T. Of these, the p.R1441G mutation is particularly frequent, as it represents a
      founder mutation in the Basque population where it is responsible for 46% of all familial PD.
      Very rarely, this mutation has also been observed in other populations where it arose on a
      different haplotype. LRRK2 p.Gly2019Ser mutation accounts for about 0.5% simplex cases and
      &gt;5% familial cases in various ethnic groups worldwide. Furthermore, genome-wide association
      studies have identified common polymorphisms in LRRK2 that associate with idiopathic PD,
      implicating LRRK2 function in susceptibility to late-onset PD in individuals without
      pathogenic mutations.

      LRRK2 mutations cause PD with age-related penetrance and clinical features identical to
      late-onset sporadic PD. Biochemical studies support an increase in Lrrk2 kinase activity and
      a decrease in GTPase activity for kinase domain and Roc-COR mutations, respectively. Strong
      evidence exists that Lrrk2 toxicity is kinase dependent, leading to extensive efforts to
      identify selective and brain-permeable Lrrk2 kinase inhibitors for clinical development.
      Lrrk2 kinase inhibition is currently one of the most prevailing disease-modifying therapeutic
      strategies for PD. Thus, Lrrk2 kinase inhibitors are in development as potential Parkinson's
      disease therapeutics.

      Furthermore, there is now evidence showing that LRRK2 expression and phosphorylation levels
      have a potential as markers of Parkinson's disease. Recently, the presence of Lrrk2 was
      confirmed in exosomes from human biofluids, including urine and cerebrospinal fluid.
      Moreover, elevated LRRK2 autophosphorylation was identified in brain-derived and peripheral
      exosomes in LRRK2-mutation carriers. In summary, it has been shown that markers of Lrrk2
      activity and function may be detected in human blood and that they are relevant for
      pathogenesis if PD.

      Thus, the biochemical analyses of human blood from LRRK2 positive participants and LRRK2
      negative participants create a strong base for the development of PD-related biomarkers. This
      biomarker may in turn be even more accessible than genetic testing and it may serve for
      diagnosis, prognosis, and prediction of PD.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 30, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>To identify 1,500 LRRK2-positive participants</measure>
    <time_frame>2 years</time_frame>
    <description>The participants fulfilling the eligibility criteria will be enrolled into the Study and genetically tested for LRRK2 hotspot mutations and the whole GBA gene will be sequenced.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To identify 1,500 non-LRRK2 PD participants</measure>
    <time_frame>2 years</time_frame>
    <description>Participants with negative results for LRRK2 hotspots and GBA, clinically diagnosed for PD and are willing to participate in further genetic screening, 68 PD associated genes will be sequenced.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Establishment of candidate LRRK2-positive biomarkers in the LRRK2-positive cohort</measure>
    <time_frame>2 years</time_frame>
    <description>LRRK2-positive samples will be validated for the identification of potential biomarkers (based on MS/MS-Spectroscopy) and compared with a merged control sample in order to establish a LRRK2 specific biomarker.</description>
  </other_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">10000</enrollment>
  <condition>Parkinson´s Disease</condition>
  <arm_group>
    <arm_group_label>Parkinson´s disease individuals</arm_group_label>
    <description>The participants that are clinically diagnosed with Parkinson's disease</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Family member of a participant with LRRK2 parkinsonism</arm_group_label>
    <description>The first and second degree family members of the ROPAD Study participants with LRRK2 parkinsonism</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High risk population</arm_group_label>
    <description>Populations at high risk such as Ashkenazi Jewish and Arab Berber</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood sample applied on the Dry Blood Spot (DBS) Filtercard (Centocard®)
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Parkinson's disease patients and LRRK2 carriers and high risk population
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Informed consent is obtained from the participant.

          -  The participant is equal to or older than 18 years old.

          -  The participant is clinically diagnosed with Parkinson's disease

          -  The participant is a family member of a participant with LRRK2 parkinsonism.

          -  The participant is a member of a high risk population.

        Exclusion Criteria:

          -  Inability to provide informed consent.

          -  The participant is younger than 18 years old.

          -  The participant is not suffering from Parkinson's disease.

          -  The participant is not a family member of a participant with LRRK2 parkinsonism.

          -  The participant is not a member of a high risk population.

          -  Previously enrolled in the study.

          -  Participant in custody.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Arndt Rolfs, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centogene AG Rostock</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Volha Skrahina, PhD</last_name>
    <phone>+49 (0)38180113594</phone>
    <email>volha.skrahina@centogene.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Hanaa Gaber, PhD</last_name>
    <phone>+49 (0)38180113633</phone>
    <email>hanaa.gaber@centogene.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Tucson Neuroscience Research</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roderick Anderson, MD</last_name>
      <phone>520-829-7502</phone>
      <email>landerson@tarheelclinical.com</email>
    </contact>
    <investigator>
      <last_name>Roderick Anderson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Pharmacology Research Institute</name>
      <address>
        <city>Encino</city>
        <state>California</state>
        <zip>91316</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mark Pulera, MD</last_name>
      <phone>818-705-7451</phone>
      <email>mpulera@priresearch.com</email>
    </contact>
    <investigator>
      <last_name>Mark Pulera, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Neuro-Pain Medical Center</name>
      <address>
        <city>Fresno</city>
        <state>California</state>
        <zip>93710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Perminder Bhatia, MD</last_name>
      <phone>559-437-9700</phone>
      <email>bhatia@neuropain.com</email>
    </contact>
    <investigator>
      <last_name>Perminder Bhatia, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California (UC) San Diego</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Raelyn Vogel</last_name>
      <phone>858-246-4894</phone>
      <email>rvogel@health.ucsd.edu</email>
    </contact>
    <investigator>
      <last_name>Irene Litvan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Pharmacology Research Institute</name>
      <address>
        <city>Los Alamitos</city>
        <state>California</state>
        <zip>90720</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Rosenberg, MD</last_name>
      <phone>714-827-3667</phone>
      <email>drosenberg@tarhellclinical.com</email>
    </contact>
    <investigator>
      <last_name>David Rosenberg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Pharmacology Research Institute</name>
      <address>
        <city>Newport Beach</city>
        <state>California</state>
        <zip>92660</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nader Oskooilar, MD</last_name>
      <phone>949-752-7910</phone>
      <email>noskooilar@tarheelclinical.com</email>
    </contact>
    <investigator>
      <last_name>Nader Oskooilar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Parkinson's Disease and Movement Disorder Center of Baco Raton</name>
      <address>
        <city>Boca Raton</city>
        <state>Florida</state>
        <zip>33486</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stuart Isaacson, MD</last_name>
      <phone>561-392-1818</phone>
      <email>Pdgenestudy@parkinsonscenter.org</email>
    </contact>
    <investigator>
      <last_name>Stuart Isaacson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Linfritz Research Institute</name>
      <address>
        <city>Coral Gables</city>
        <state>Florida</state>
        <zip>33134</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Diego Rielo, MD</last_name>
      <phone>786-953-7279</phone>
      <email>rielo@linfritz.com</email>
    </contact>
    <investigator>
      <last_name>Diego Rielo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Renstar Medical Research</name>
      <address>
        <city>Ocala</city>
        <state>Florida</state>
        <zip>34475</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anette Nieves, MD</last_name>
      <phone>352-732-9643</phone>
      <email>anette.nieves@renstar.net</email>
    </contact>
    <investigator>
      <last_name>Anette Nieves, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vero Beach Neurology &amp; Research Institute</name>
      <address>
        <city>Vero Beach</city>
        <state>Florida</state>
        <zip>32960</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stuart Shafer, MD</last_name>
      <phone>772-492-7051</phone>
      <email>stjashafer@aol.com</email>
    </contact>
    <investigator>
      <last_name>Stuart Shafer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rush University Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gian Pal, MD</last_name>
      <phone>312-563-4772</phone>
      <email>Gian_D_Pal@rush.edu</email>
    </contact>
    <investigator>
      <last_name>Gian Pal, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northshore University HealthSystem</name>
      <address>
        <city>Evanston</city>
        <state>Illinois</state>
        <zip>60201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anna Pham</last_name>
      <phone>847-570-2570</phone>
      <email>APham@northshore.org</email>
    </contact>
    <investigator>
      <last_name>Aikaterini Markopoulou, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Indiana University, Department of Neurology</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joanne Wojcieszek, MD</last_name>
      <phone>317-963-7415</phone>
      <email>jwojcies@iupui.edu</email>
    </contact>
    <investigator>
      <last_name>Joanne Wojcieszek, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Michigan Institute for Neurological Disorders</name>
      <address>
        <city>Farmington Hills</city>
        <state>Michigan</state>
        <zip>48334</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aaron Ellenbogen, MD</last_name>
      <phone>248-553-0010</phone>
      <email>aaron@questri.com</email>
    </contact>
    <investigator>
      <last_name>Aaron Ellenbogen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>WR-CRCN</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Simon Farrow, MD</last_name>
      <phone>423-698-4584</phone>
      <email>mmckenzie@tarheelclinical.com</email>
    </contact>
    <investigator>
      <last_name>Simon Farrow, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Neuroscience Research Institute of NJ</name>
      <address>
        <city>Toms River</city>
        <state>New Jersey</state>
        <zip>08755</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gerald Ferencz, MD</last_name>
      <phone>732-341-9500</phone>
      <email>gjayfmd@aol.com</email>
    </contact>
    <investigator>
      <last_name>Gerald Ferencz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dent Neurologic Institue</name>
      <address>
        <city>Amherst</city>
        <state>New York</state>
        <zip>14226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bennett Myers, MD</last_name>
      <phone>716-250-2000</phone>
      <email>bmyers@dentinstitute.com</email>
    </contact>
    <investigator>
      <last_name>Bennett Myers, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Stony Brook University School of Medicine</name>
      <address>
        <city>Brookhaven</city>
        <state>New York</state>
        <zip>11772</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carine Maurer, MD</last_name>
      <phone>631-444-2599</phone>
      <email>carine.maurer@stonybrookmedicine.edu</email>
    </contact>
    <investigator>
      <last_name>Carine Maurer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>South Shore Neurologic Associates</name>
      <address>
        <city>Patchogue</city>
        <state>New York</state>
        <zip>11772</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mark Gudesblatt, MD</last_name>
      <phone>631-758-1910</phone>
      <email>mark.gudesblatt.md@southshoreneurologic.com</email>
    </contact>
    <investigator>
      <last_name>Mark Gudesblatt, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Duke University, Department of Neurology</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Burton Scott, MD</last_name>
      <phone>919-668-2493</phone>
      <email>scott007@mc.duke.edu</email>
    </contact>
    <investigator>
      <last_name>Burton Scott, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>M3 Wake Research, Inc.</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Singar Jagadeesan, MD</last_name>
      <phone>919-781-2514</phone>
      <email>sjagadeesan@wakeresearch.com</email>
    </contact>
    <investigator>
      <last_name>Singar Jagadeesan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>WR-ClinSearch, LLC</name>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <zip>37421</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mark McKenzie, MD</last_name>
      <phone>423-698-4584</phone>
      <email>mmckenzie@tarheelclinical.com</email>
    </contact>
    <investigator>
      <last_name>Mark McKenzie, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Booth Gardner Parkinson's Care Center</name>
      <address>
        <city>Kirkland</city>
        <state>Washington</state>
        <zip>98034</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pinky Agarwal, MD</last_name>
      <phone>425-899-3123</phone>
      <email>pagarwal@evergreenhealthcare.org</email>
    </contact>
    <investigator>
      <last_name>Pinky Agarwal, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Inland Northwest Research</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sarah Brauneis, BS</last_name>
      <phone>509-960-2818</phone>
      <email>SBrauneis@inwresearch.com</email>
    </contact>
    <investigator>
      <last_name>Jason Aldred, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Qendra Spitalore University</name>
      <address>
        <city>Tirana</city>
        <country>Albania</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paskal Cullufi, MD</last_name>
      <email>paskal_cullufi@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Paskal Cullufi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UZ Leuven, campus Gasthuisberg</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wim Vandenberghe, MD</last_name>
      <email>wim.vandenberghe@uzleuven.be</email>
    </contact>
    <investigator>
      <last_name>Wim Vandenberghe, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Angelina Caron</name>
      <address>
        <city>Curitiba</city>
        <zip>82530050</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Giorgio Fabiani, MD</last_name>
      <phone>+55 (0)4136798100</phone>
      <email>giorgiofabiani@icloud.com</email>
    </contact>
    <investigator>
      <last_name>Giorgio Fabiani, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Sirio-Libanes</name>
      <address>
        <city>São Paulo</city>
        <zip>01308-050</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erich Fonoff, MD</last_name>
      <phone>+55 (0)1132372031</phone>
      <email>fonoffet@usp.br</email>
    </contact>
    <investigator>
      <last_name>Erich Fonoff, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Neurologisches Fachkrankenhaus für Bewegungsstörungen / Parkinson</name>
      <address>
        <city>Beelitz</city>
        <zip>14547</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Georg Ebersbach, MD</last_name>
      <phone>+49 (0)3320422785</phone>
      <email>gruber@kliniken-beelitz.de</email>
    </contact>
    <investigator>
      <last_name>Georg Ebersbach, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Charite University Medicine</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrea Kühn, MD</last_name>
      <phone>+49 (0)30450660123</phone>
      <email>andrea.kuehn@charite.de</email>
    </contact>
    <investigator>
      <last_name>Andrea Kühn, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Friederike Borngräber, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gertrudis-Kliniken im Parkison-Zentrum</name>
      <address>
        <city>Biskirchen</city>
        <zip>35638</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ilona Csoti, MD</last_name>
      <phone>+49 (0)64733058011</phone>
      <email>ilona.csoti@parkinson.de</email>
    </contact>
    <investigator>
      <last_name>Ilona Csoti, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Carl Gustav Carus die Dresdner</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Björn Falkenburger, MD</last_name>
      <phone>+49 (0)35145819783</phone>
      <email>Bjoern.Falkenburger@uniklinikum-dresden.de</email>
    </contact>
    <investigator>
      <last_name>Björn Falkenburger, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinik Hamburg-Eppendorf</name>
      <address>
        <city>Hamburg-Eppendorf</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Simone Zittel-Dirks, MD</last_name>
      <phone>+49 (0)40741053770</phone>
      <email>gerloff@uke.de</email>
    </contact>
    <investigator>
      <last_name>Simone Zittel-Dirks, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Asklepios Klinik Barmbek</name>
      <address>
        <city>Hamburg</city>
        <zip>22291</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter P. Urban, Prof.</last_name>
      <phone>+49 (0)401818853072</phone>
      <email>p.urban@asklepios.com</email>
    </contact>
    <investigator>
      <last_name>Peter P. Urban, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinik für Neurologie</name>
      <address>
        <city>Jena</city>
        <zip>7740</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tino Prell, MD</last_name>
      <email>tino.prell@med.uni-jena.de</email>
    </contact>
    <investigator>
      <last_name>Tino Prell, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Schleswig-Holstein, Klinik für Neurologie</name>
      <address>
        <city>Kiel</city>
        <zip>24105</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniela Berg, MD</last_name>
      <phone>+49 (0)431 500 23986</phone>
      <email>Daniela.Berg@uksh.de</email>
    </contact>
    <investigator>
      <last_name>Daniela Berg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institute of Neurogenetic</name>
      <address>
        <city>Luebeck</city>
        <zip>23562</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christine Klein, Prof.</last_name>
      <phone>+49 (0)45131018200</phone>
      <email>christine.klein@neuro.uni-luebeck.de</email>
    </contact>
    <investigator>
      <last_name>Christine Klein, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Marburg Klinik und Poliklinik für Neurologie Parkinson Netzwerk Allianz Marburg (PANAMA)</name>
      <address>
        <city>Marburg</city>
        <zip>35043</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Crsten Eggers, MD</last_name>
      <phone>+49 (0)64215865299</phone>
      <email>carsten.eggers@uk-gm.de</email>
    </contact>
    <investigator>
      <last_name>Crsten Eggers, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitatsklinik fur Neurologie</name>
      <address>
        <city>Münster</city>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tobias Warnecke, MD</last_name>
      <phone>+49 (0)2518346081</phone>
      <email>Tobias.Warnecke@ukmuenster.de</email>
    </contact>
    <investigator>
      <last_name>Tobias Warnecke, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Asklepios Fachklinikum Stadtroda Klinik für Neurologie, Schmerztherapie und Schlafmedizin</name>
      <address>
        <city>Stadtroda</city>
        <zip>07646</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Weise, MD</last_name>
      <phone>+49 (0)3648561375</phone>
      <email>da.weise@asklepios.com</email>
    </contact>
    <investigator>
      <last_name>David Weise, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mediterraneo Hospital</name>
      <address>
        <city>Athens</city>
        <zip>16675</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pantelis Stathis, MD</last_name>
      <phone>+30 (0)2109117031</phone>
      <email>stathis.pantelis@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Pantelis Stathis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hadassah Medical Center</name>
      <address>
        <city>Jerusalem</city>
        <zip>91120</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Arkadir, MD</last_name>
      <phone>+972 (0)532801520</phone>
      <email>arkadir@hadassah.org.il</email>
    </contact>
    <investigator>
      <last_name>David Arkadir, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Università di Pavia, Dipartimento di Medicina Molecolare</name>
      <address>
        <city>Pavia</city>
        <zip>27100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Enza Maria Valente, MD</last_name>
      <email>enzamaria.valente@unipv.it</email>
    </contact>
    <investigator>
      <last_name>Enza Maria Valente, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Asmn - Irccs</name>
      <address>
        <city>Reggio Emilia</city>
        <zip>42123</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Franco Valzania, MD</last_name>
      <email>Franco.Valzania@ausl.re.it</email>
    </contact>
    <investigator>
      <last_name>Franco Valzania, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>I.R.C.C.S. San Raffaele Pisana</name>
      <address>
        <city>Roma</city>
        <zip>00163</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fabrizio Stocchi, MD</last_name>
      <email>parkinson@sanraffaele.it</email>
    </contact>
    <investigator>
      <last_name>Fabrizio Stocchi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Fundación Alcorcón</name>
      <address>
        <city>Alcorcón</city>
        <zip>28922</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lydia Vela, MD</last_name>
      <phone>+34 (0)650385989</phone>
      <email>lvela@fhalcorcon.es</email>
    </contact>
    <investigator>
      <last_name>Lydia Vela, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>HM CINAC | Integrated Neuroscience Center</name>
      <address>
        <city>Madrid</city>
        <zip>28938</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michele Matarazzo, MD</last_name>
      <phone>+34 (0)912673201</phone>
      <email>mmatarazzo.hmcinac@mail.hmhospitales.com</email>
    </contact>
    <investigator>
      <last_name>Michele Matarazzo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Marqués de Valdecilla</name>
      <address>
        <city>Santander</city>
        <zip>39008</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jon Infante, MD</last_name>
      <email>jon.infante@scsalud.es</email>
    </contact>
    <investigator>
      <last_name>Jon Infante, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cukurova University Faculty of Medicine</name>
      <address>
        <city>Sarıçam</city>
        <state>Adana</state>
        <zip>01790</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Duruhan Demirkıran, MD</last_name>
      <phone>+90 (0)3223386060</phone>
      <phone_ext>3206</phone_ext>
      <email>meltemdd@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Duruhan Demirkıran, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Istanbul Faculty of Medicine</name>
      <address>
        <city>Istanbul</city>
        <zip>34093</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Haşmet Hanağası, MD</last_name>
      <phone>+90 (0)5322728519</phone>
      <email>hasmet@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Haşmet Hanağası, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mersin Faculty of Medicine</name>
      <address>
        <city>Mersin</city>
        <zip>33110</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Okan Doğu, MD</last_name>
      <phone>+90 (0)5446604010</phone>
      <email>doguokan@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Okan Doğu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fairfield General Hospital</name>
      <address>
        <city>Bury</city>
        <zip>BL9 7TD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jason Raw, MD</last_name>
      <phone>+44 (0)1617783707</phone>
      <email>jason.raw@pat.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Jason Raw, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Dundee</name>
      <address>
        <city>Dundee</city>
        <zip>DD1 5EH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Esther Sammler, MD</last_name>
      <phone>+44 (0)1382386698</phone>
      <email>e.m.sammler@dundee.ac.uk</email>
    </contact>
    <investigator>
      <last_name>Esther Sammler, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Devon and Exeter Hospital</name>
      <address>
        <city>Exeter</city>
        <zip>EX2 5DW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ray Sheridan, MD</last_name>
      <phone>+44 (0)1392402760</phone>
      <email>ray.sheridan@nhs.net</email>
    </contact>
    <investigator>
      <last_name>Ray Sheridan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Oxford, Nuffield Department of Clinical Neurosciences</name>
      <address>
        <city>Oxford</city>
        <zip>OX3 9DU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michele Hu, MD</last_name>
      <phone>+44 (0)1865223166</phone>
      <email>Lorraine.Johns@ouh.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Michele Hu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Salford Royal NHS Foundation Trust</name>
      <address>
        <city>Salford</city>
        <zip>M6 8HD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Monty Silverdale, MD</last_name>
      <phone>+44 (0)1625661782</phone>
      <email>SalfordRDAmendments@srft.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Monty Silverdale, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Yeovil District Hospital</name>
      <address>
        <city>Yeovil</city>
        <zip>BA21 4AT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rani Sophia, MD</last_name>
      <phone>+44 (0)1935384615</phone>
      <email>rani.sophia@ydh.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Rani Sophia, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Albania</country>
    <country>Belgium</country>
    <country>Brazil</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Spain</country>
    <country>Turkey</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Baumann CR. Epidemiology, diagnosis and differential diagnosis in Parkinson's disease tremor. Parkinsonism Relat Disord. 2012 Jan;18 Suppl 1:S90-2. doi: 10.1016/S1353-8020(11)70029-3. Review.</citation>
    <PMID>22166466</PMID>
  </results_reference>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>March 1, 2019</study_first_submitted>
  <study_first_submitted_qc>March 6, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 7, 2019</study_first_posted>
  <last_update_submitted>June 25, 2020</last_update_submitted>
  <last_update_submitted_qc>June 25, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 26, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Parkinson´s disease</keyword>
  <keyword>Biomarker</keyword>
  <keyword>LRRK2</keyword>
  <keyword>GBA</keyword>
  <keyword>PD Genetics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>The plan will be defined at a later stages</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

